Centrum Onkologii

Recent papers from Centrum Onkologii

1. AI-assisted immunohistochemistry algorithm for enriching HER2-amplified cases among equivocal (2+) breast cancers: a two-cohort proof-of-concept studyBMC Cancer · 2026
2. A phase 2a study with SPL84: A novel RNA-targeted approach to restore CFTR function in people with CF carrying the 3849+10 kb C→T mutationEuropean Respiratory Journal · 2026
3. Phenotype-guided myofascial treatment package versus a fixed massage-based manual therapy comparator for pain sensitivity and muscle stiffness in non-specific neck pain: a randomized controlled trialScientific Reports · 2026
4. Nivolumab plus chemotherapy or ipilimumab versus chemotherapy as first-line treatment for advanced esophageal squamous cell carcinoma: 5-year follow-up results from CheckMate 648Annals of Oncology · 2026
5. SERENA-6 visual patient-reported outcomes & safety: camizestrant for emerging ESR1 m advanced breast cancer during first-line endocrine-basedtherapyThe Oncologist · 2026
6. Multiple primary head and neck cancers: a scenario-based framework for diagnosis and modern multidisciplinary managementFrontiers in Oncology · 2026
7. Geometrical prediction model for late rectal bleeding in radiotherapy of prostate cancerPolish Journal of Medical Physics And Engineering · 2026
8. Comparison of real-world effectiveness of all approved BRAF/MEK inhibitor combinations in BRAF -mutant melanoma patients.Journal of Clinical Oncology · 2026
9. Heterogeneity in biomarkers for advanced gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma (GC/GEJC/EAC) across regions: Insights from CheckMate-649.Journal of Clinical Oncology · 2026
10. Neurocognition after brain irradiation: dose-volume effects and regional radiosensitivity − a systematic review by the ESTRO CNS focus groupRadiotherapy and Oncology · 2026
11. Assessment of additional anxiety caused by COVID-19 in cancer patients during the pandemic using the Hamilton Anxiety ScaleAcibadem Universitesi Saglik Bilimleri Dergisi · 2026
12. Phase II study of magrolimab combined with docetaxel in previously treated metastatic advanced solid tumorsFrontiers in Oncology · 2026
13. Abstract CT003: Initial results of a phase 1 study of AMG 355, a novel anti-CCR8 antibody as a single agent and in combination with pembrolizumab in patients with solid tumorsCancer Research · 2026
14. Abstract LB331: First-line (1L) trastuzumab deruxtecan (T-DXd) + rilvegostomig (rilve) + fluoropyrimidine (FP) in HER2-positive (HER2+) gastric cancer (GC), gastroesophageal junction adenocarcinoma (GEJA), or esophageal adenocarcinoma (EA): DESTINY-Gastric03 (DG-03) Part 4 arm A resultsCancer Research · 2026
15. 4MO Updated results for MK-1084 + pembrolizumab in KRAS G12C-mutated (mut) metastatic non-small cell lung cancer (mNSCLC) enrolled in KANDLELIT-001ESMO Open · 2026
16. 92P IMMUNOLung80: Outcomes of first-line immunotherapy in octogenarians with advanced NSCLC - A multicentre studyESMO Open · 2026
17. Hepatitis A Virus Infection: Epidemiology, Diagnosis, and Prevention in the 21st Century2026
18. The TEXTAROSSA project: Cool all the Way Down to the HardwareMicroprocessors and Microsystems · 2026
19. Abstract PD10-04: Visual functioning and characterization of visual effects from SERENA-6, a Phase 3 study of switch to camizestrant (CAMI) from aromatase inhibitor (AI) while continuing CDK4/6 inhibitor (CDK4/6i) at emergence of ESR1 mutations (ESR1m) during first-line therapy for patients (pts) with HR+/HER2− advanced breast cancer (ABC)Clinical Cancer Research · 2026
20. Abstract RF7-03: Updated results and an exploratory analysis of ESR1m circulating tumor DNA (ctDNA) dynamics from SERENA-6, a phase 3 trial of camizestrant (CAMI) + CDK4/6 inhibitor (CDK4/6i) for emergent ESR1 mutations (ESR1m) during first-line (1L) endocrine-based therapy and ahead of disease progression in patients (pts) with HR+/HER2- advanced breast cancer (ABC)Clinical Cancer Research · 2026